LENZ LENZ Therapeutics Inc.
Price (delayed)
$21.05
Market cap
$578.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.46
Enterprise value
$495.71M
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process
Highlights
LENZ Therapeutics's quick ratio has soared by 102% from the previous quarter and by 13% YoY
LENZ Therapeutics's debt has shrunk by 98% YoY
The equity has declined by 14% year-on-year and by 2.6% since the previous quarter
Key stats
What are the main financial stats of LENZ
Market
Valuations
Earnings
Shares outstanding
27.5M
Market cap
$578.8M
Enterprise value
$495.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$72.31M
EBITDA
-$69.9M
Free cash flow
-$98.44M
Per share
Balance sheet
Liquidity
EPS
-$9.46
Free cash flow per share
-$3.84
Book value per share
$7.56
Revenue per share
$0
TBVPS
$7.91
Total assets
$202.64M
Total liabilities
$9.72M
Debt
$1.05M
Equity
$192.92M
Working capital
$190.77M
Debt to equity
0.01
Current ratio
23.23
Quick ratio
22.86
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.2%
Return on equity
-57.6%
Return on invested capital
-116.6%
Return on capital employed
-37.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LENZ stock price
How has the LENZ Therapeutics stock price performed over time
Intraday
-3.71%
1 week
-12.98%
1 month
-7.47%
1 year
30.75%
YTD
14.78%
QTD
21.75%
Financial performance
How have LENZ Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.02M
Net income
-$72.31M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 6% QoQ and by 6% YoY
Growth
What is LENZ Therapeutics's growth rate over time
Valuation
What is LENZ Therapeutics stock price valuation
P/E
N/A
P/B
2.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 53% YoY and by 43% from the previous quarter
The equity has declined by 14% year-on-year and by 2.6% since the previous quarter
Efficiency
How efficient is LENZ Therapeutics business performance
LENZ Therapeutics's ROE has plunged by 109% YoY
LENZ's return on assets has dropped by 56% year-on-year and by 4.7% since the previous quarter
The return on invested capital has declined by 27% since the previous quarter
Dividends
What is LENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LENZ.
Financial health
How did LENZ Therapeutics financials performed over time
LENZ Therapeutics's current ratio has soared by 103% from the previous quarter and by 13% YoY
LENZ Therapeutics's quick ratio has soared by 102% from the previous quarter and by 13% YoY
LENZ Therapeutics's debt is 99% lower than its equity
LENZ Therapeutics's debt has shrunk by 98% YoY
LENZ Therapeutics's debt to equity has plunged by 96% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.